FDA Propels Insulin Affordability with Semglee insulin

The FDA propels insulin affordability by approving Semglee as an “interchangable biosimilar” insulin.

 
Now pharmacists can substitute the much cheaper Semglee for Lantus without having to consult the prescribing healthcare professional- potentially providing a more affordable alternative

Semglee is now a cheaper alternative for insulin for adults and children with Type 1 Diabetes and adults with Type 2 Diabetes. 

Semglee is available by prescription in either a pen or vial form with a cost of $147.98 for five 3 ml prefilled pens or $98.65 for one 10 ml vial,
which is a 65% discount from the price of Lantus (a more common brand of insulin)